Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance.

Xiong, Jin; Xia, Lei

Xiong, Jin; Xia, Lei.

Afiliación

Xiong J; Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xia L; Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Front Oncol ; 14: 1419306, 2024.

Article en En | MEDLINE | ID: mdl-38978737

ABSTRACT

ABSTRACT

Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutations and combining ALK-TKIs with angiogenic agents may improve survival. We report here one case with ALK-positive lung adenocarcinoma in which the patient achieved a prolonged progression-free survival (PFS) of 97 months after undergoing precise pleural effusion NGS and receiving combined bevacizumab treatment following multiple-line ALK-TKI resistance.

Palabras clave

case report; combination therapy; long-term survival; multiple-line ALK-TKI; pleural effusion NGS

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google